Oracle names Stephen Rusckowski to board of directors

AUSTIN - Oracle Corporation (NYSE:ORCL) has elected Stephen Rusckowski to its Board of Directors, expanding the board to 14 members, the company announced Thursday. The tech giant, with a market capitalization of $603.4 billion and trading at a P/E ratio of 49.72, continues to strengthen its leadership team as it trades slightly above its InvestingPro Fair Value.

Rusckowski, the former Chief Executive Officer and President of Quest Diagnostics, Inc. from 2012 to 2022, joined Oracle’s board effective November 18, 2025. He also served as Chair of Quest’s Board from January 2017 through March 2023.

Prior to his tenure at Quest, Rusckowski was Chief Executive Officer of Philips Healthcare and a member of the Board of Management of Royal Philips Electronics. He currently serves on the supervisory board of Qiagen N.V. and as a director of Baxter International Inc.

Larry Ellison, Oracle’s Board Chairman and Chief Technology Officer, stated that Rusckowski’s experience in healthcare and technology would provide "a unique perspective as to how Oracle Health can better serve patients and healthcare providers around the world." This strategic focus on healthcare comes as Oracle, a prominent player in the software industry according to InvestingPro data, has seen its revenue grow 9.67% to $59.02 billion in the last twelve months.

Bruce Chizen, Chair of the Nomination and Governance Committee, expressed confidence that Oracle and its stakeholders would benefit from Rusckowski’s "extensive experience in leading and advising global healthcare organizations."

Rusckowski holds a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute and a Master of Science degree in Management from MIT’s Sloan School of Management.

Oracle board members serve one-year terms and will next stand for election at the company’s annual meeting of stockholders in November 2026, according to the press release statement. Investors should note that Oracle has maintained dividend payments for 17 consecutive years and has raised its dividend for 12 straight years, with shares showing strong momentum, up 34.56% over the past six months. The company is scheduled to report its next quarterly earnings on December 15, 2025. InvestingPro offers comprehensive research reports on Oracle and 1,400+ other US equities, providing deeper insights into what really matters for informed investment decisions.

In other recent news, Oracle has been designated as a Qualified Health Information Network (QHIN) under the Trusted Exchange Framework and Common Agreement (TEFCA). This allows Oracle Health customers to participate in a nationwide health information exchange system, enhancing secure data sharing across various sectors. Additionally, Oracle is part of a group of technology hyperscalers that have issued a record $121 billion in investment-grade debt this year, significantly surpassing the five-year average. This debt issuance includes $81 billion from major companies like Amazon, Alphabet, Meta, and Microsoft, alongside Oracle.

In related developments, Erste Group has downgraded Oracle’s stock rating from Buy to Hold, citing the company’s substantial investments in cloud infrastructure. These investments include the expansion of cloud offerings and new data centers, contributing to significant growth in this segment. Furthermore, Oracle Health and Life Sciences has formed a strategic alliance with the Cancer Center Informatics Society (Ci4CC) to advance AI innovation in oncology care and research. This collaboration aims to integrate clinical and genomic data for personalized medicine and develop AI-driven approaches for clinical trials. Meanwhile, Saba Capital Management has been selling credit derivatives to banks hedging against potential losses on tech companies, including those with AI investments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.